Health care biotech companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Biogen has the lowest figure of the 19 health care biotech companies ranked by P/S ratio, at 3.7, followed by Qiagen (4.9) and Neurocrine Biosciences (5.6). Figures as of 19 Nov 2026, 20:39 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- Lowest
- Biogen3.7
- Median
- 14.3
- Combined market value
- CHF 699.5B
- Countries
- 5
- Not ranked
- 5no P/S ratio on file
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 3.7 | CHF 30.7B | CHF 207.69 | 2.10% down | 49% up | ||
| 2 | QiagenQGEN · Health Care | 4.9 | CHF 8.6B | CHF 41.80 | 0.05% down | 9% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 5.6 | CHF 13.5B | CHF 133.13 | 3.12% down | 17% up | ||
| 4 | BioNTechBNTX · Health Care | 6.3 | CHF 17B | CHF 68.41 | 2.62% down | 14% down | ||
| 5 | AmgenAMGN · Health Care | 6.5 | CHF 200.4B | CHF 370.58 | 1.06% down | 32% up | ||
| 6 | ExelixisEXEL · Health Care | 6.9 | CHF 13.5B | CHF 55.52 | 3.65% down | 63% up | ||
| 7 | Gilead SciencesGILD · Health Care | 7.0 | CHF 174.7B | CHF 140.82 | 1.23% down | 35% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | 7.6 | CHF 8.9B | CHF 78.31 | 3.12% down | 39% up | ||
| 9 | Bio-TechneTECH · Health Care | 9.4 | CHF 9.6B | CHF 61.35 | 0.06% down | 24% up | ||
| 10 | argenxARGX · Health Care | 14.3 | CHF 49.9B | CHF 794.01 | 0.02% down | 2% up | ||
| 11 | RepligenRGEN · Health Care | 14.7 | CHF 9.2B | CHF 143.66 | 1.39% down | 12% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | 16.5 | CHF 3.9B | CHF 23.83 | 0.77% down | 74% up | ||
| 13 | Twist BioscienceTWST · Health Care | 20.4 | CHF 6.5B | CHF 95.00 | 3.23% down | 346% up | ||
| 14 | Krystal BiotechKRYS · Health Care | 24.0 | CHF 7.9B | CHF 265.91 | 0.06% down | 54% up | ||
| 15 | ModernaMRNA · Health Care | 41.6 | CHF 68.2B | CHF 168.54 | 1.50% up | 780% up | ||
| 16 | ImmunityBioIBRX · Health Care | 61.2 | CHF 5.8B | CHF 5.50 | 2.76% down | 232% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | 260 | CHF 8.6B | CHF 100.91 | 1.27% down | 87% up | ||
| 18 | CRISPR TherapeuticsCRSP · Health Care | 1076 | CHF 3.2B | CHF 32.86 | 3.11% down | 18% down | ||
| 19 | CG OncologyCGON · Health Care | 1806 | CHF 6.2B | CHF 68.94 | 2.14% up | 97% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8438 CHF). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which health care biotech companies have the lowest P/S ratio?
Biogen (3.7), Qiagen (4.9) and Neurocrine Biosciences (5.6) have the lowest P/S ratio of the 19 health care biotech companies ranked here as of 19 Nov 2026, 20:39 UTC.
How many health care biotech companies are in this ranking?
19 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these health care biotech companies worth together?
The 19 health care biotech companies ranked by P/S ratio have a combined market value of CHF 699.5B as of 19 Nov 2026, 20:39 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care biotech companies by P/S ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.